Publications: Policy Briefs


Assessing the State of Play in the WHO Pandemic Instrument Negotiations
 Policy Brief 121, 18 July 2023

Viviana Muñoz Tellez
Hacia una Agencia Latinoamericana y del Caribe de Medicamentos (AMLAC)
 Informe Sobre Políticas 120, 11 de Julio de 2022

Germán Velásquez
Towards A Latin American and Caribbean Medicines Agency (AMLAC)
 Policy Brief 120, 11 July 2023

Germán Velásquez
La incorporación de la equidad en el Reglamento Sanitario Internacional y en futuros instrumentos jurídicos de la OMS sobre preparación y respuesta frente a pandemias
 Informe sobre políticas No. 108, 25 de marzo de 2022

Nirmalya Syam
L’intégration de l’équité dans le Règlement sanitaire international et les futurs instruments juridiques de l’OMS sur la préparation et la riposte aux pandémies
 Rapport sur les politiques No. 108, 25 mars 2022

Nirmalya Syam
Analysis of the Outcome Text of the Informal Quadrilateral Discussions on the TRIPS COVID-19 Waiver
 Policy Brief 110, 5 May 2022

Carlos M. Correa and Nirmalya Syam
Mainstreaming Equity in the International Health Regulations and Future WHO Legal Instruments on Pandemic Preparedness and Response
 Policy Brief 108, 25 March 2022

Nirmalya Syam
Potential Claims related to IP and Public Health in Investment Agreements: COVID-19, the Proposed TRIPS Waiver and Beyond
 Investment Policy Brief 24, 9 December 2021

Cynthia Ho
The Doha Ministerial Declaration on TRIPS and Public Health on its Twentieth Anniversary
 Policy Brief 107, November 2021

Nirmalya Syam, Viviana Munoz, Carlos M. Correa and Vitor Ido
Strengthening WHO for Future Health Emergencies while Battling COVID-19: Major Outcomes of the 2021 World Health Assembly
 Policy Brief 106, November 2021

Nirmalya Syam and Mirza Alas
Compulsory licensing vs. the IP waiver: what is the best way to end the COVID-19 pandemic?
 Policy Brief 104, October 2021

Dr. Olga Gurgula
Accelerating COVID-19 Vaccine Production via Involuntary Technology Transfer
 Policy Brief 102, September 2021

Dr. Olga Gurgula
O papel dos tribunais na implementação das flexibilidades do TRIPS: Supremo Tribunal Federal (STF) do Brasil declara inconstitucionais as extensões automáticas de prazos de patentes
 Policy Brief 94, Setembro de 2021

Vitor Henrique Pinto Ido
EU Proposals regarding Article 31bis of the TRIPS Agreement in the Context of the COVID-19 Pandemic
 Policy Brief 100, August 2021

Nirmalya Syam
The TRIPS COVID-19 Waiver, Challenges for Africa and Decolonizing Intellectual Property
 Policy Brief 99, August 2021

Yousuf Vawda
The WTO TRIPS Waiver Should Help Build Vaccine Manufacturing Capacity in Africa
 Policy Brief 97, July 2021

Faizel Ismail
Precios justos para la cobertura sanitaria universal: El impacto de la judicialización de la salud
 Informe sobre políticas no 96, Julio 2021

Silvina Andrea Bracamonte y José Luis Cassinerio
Un nouveau traité international de l’OMS sur la préparation et la riposte aux pandémies : pourra-t-il répondre aux besoins des pays du Sud ?
 Rapport sur les politiques no. 93, Juillet 2021

Dr. Germán Velásquez et Nirmalya Syam
Un nuevo tratado internacional de preparación y respuesta ante pandemias: ¿Podrá atender a las necesidades del Sur Global?
 Informe sobre políticas no 93, Julio 2021

Germán Velásquez y Nirmalya Syam
The Role of Courts in Implementing TRIPS Flexibilities: Brazilian Supreme Court Rules Automatic Patent Term Extensions Unconstitutional
 Policy Brief 94, June 2021

Vitor Henrique Pinto Ido
A New WHO International Treaty on Pandemic Preparedness and Response: Can It Address the Needs of the Global South?
 Policy Brief 93, May 2021

Dr. Germán Velásquez and Nirmalya Syam
Expanding the production of COVID-19 vaccines to reach developing countries
Lift the barriers to fight the pandemic in the Global South
 Policy Brief 92, April 2021

Carlos M. Correa
Need for Extension of the LDC Transition Period Under Article 66.1 of the TRIPS Agreement Until Graduation and Beyond
 Policy Brief 88, March 2021

Nirmalya Syam
Repenser la R&D pour les produits pharmaceutiques après le choc du nouveau coronavirus COVID-19
 Rapport sur les politiques 75, Janvier 2021

Dr. Germán Velásquez
United States: An Obsolete Trade Practice Undermines Access to the Most Expensive Drugs at More Affordable Prices
 Policy Brief 83, August 2020

Maria Fabiana Jorge
The UN General Assembly Resolutions on COVID-19: Solemn Assurances for Access to Health Technologies without an Action Plan
 Policy Brief 81, July 2020

Nirmalya Syam
Intellectual Property, Innovation and Access to Health Products for COVID-19: A Review of Measures Taken by Different Countries
 Policy Brief 80, June 2020

Nirmalya Syam
Repensando la I+D para productos farmacéuticos después del choque de la Coronavirus COVID-19
 Informe Sobre Políticas 75, Mayo 2020

Germán Velásquez
La pandemia de COVID-19: el fomento de la I+D y la gestión de la propiedad intelectual para acceder a diagnósticos, medicamentos y vacunas
 Informe Sobre Políticas 73, Mayo 2020

Dr. Viviana Muñoz Tellez
La pandémie de COVID-19 : R&D et gestion de la propriété intellectuelle pour l’accès aux tests diagnostiques, aux médicaments et aux vaccins
 Rapport sur les politiques 73, Mai 2020

Dr. Viviana Muñoz Tellez
The 73rd World Health Assembly and Resolution on COVID-19: Quest of Global Solidarity for Equitable Access to Health Products
 Policy Brief 78, May 2020

Nirmalya Syam, Mirza Alas and Vitor Ido
Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock
 Policy Brief 75, April 2020

Dr. Germán Velásquez
The COVID-19 Pandemic: R&D and Intellectual Property Management for Access to Diagnostics, Medicines and Vaccines
 Policy Brief 73, April 2020

Dr. Viviana Muñoz Tellez
USMCA debe ser enmendado para asegurar el acceso a medicamentos en México
 Informe Sobre Políticas 64, Agosto de 2019

Maria Fabiana Jorge
The US-Mexico-Canada Agreement: Putting Profits Before Patients
 Policy Brief 61, May 2019

Maria Fabiana Jorge
The ‘obvious to try’ method of addressing strategic patenting: How developing countries can utilise patent law to facilitate access to medicines
 Policy Brief 59, April 2019

Olga Gurgula
Will the Amendment to the TRIPS Agreement Enhance Access to Medicines?
 Policy Brief 57, January 2019

Carlos M. Correa
The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment
 Policy Brief 54, October 2018

Germán Velásquez
The International Debate on Generic Medicines of Biological Origin
 Policy Brief 50, August 2018

Germán Velásquez
The Need to Avoid “TRIPS-Plus” Patent Clauses in Trade Agreements
 Policy Brief 37, March 2017

Martin Khor
Guidelines on Patentability and Access to Medicines
 Policy Brief 23, October 2015

Germán Velásquez